Dr. Colowick has served on our board of directors since May 2019. Since May 2017, Dr. Colowick has served as a Partner at Sofinnova Investment, Inc., a clinical stage life sciences venture capital firm. From February 2010 to April 2017, Dr. Colowick held various positions, including Executive Vice President, at Celgene Corporation, a pharmaceutical company. From February 2008 to January 2010, Dr. Colowick served as the Chief Executive Officer of Gloucester Pharmaceuticals Inc., an early stage cancer pharmaceutical company, until its acquisition by Celgene Corporation in January 2010. From October 2006 to February 2008, Dr. Colowick served as President, Oncology at Geron Corporation, an early stage pharmaceutical company. Earlier in his career, Dr. Colowick served in various capacities at Amgen Inc., a biopharmaceutical company. Dr. Colowick has served on the board of directors of Human Longevity, Inc., a genomics-based health intelligence company, since June 2016, and has served on the board of directors of Principia Biopharma Inc., a biopharmaceutical company, since February 2017. Dr. Colowick previously served on the board of directors of Achaogen, Inc., a biopharmaceutical company, from August 2015 to August 2017, and on the board of directors of Dimension Therapeutics, Inc., a biopharmaceutical company, from August 2015 to November 2017. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University School of Medicine, and an M.P.H. from the Harvard School of Public Health.